TY - JOUR
T1 - Palindromic Peptide LfcinB (21-25)Pal Exhibited Antifungal Activity against Multidrug-Resistant Candida
AU - Vargas-Casanova, Yerly
AU - Carlos Villamil Poveda, Jean
AU - Jenny Rivera-Monroy, Zuly
AU - Ceballos Garzón, Andrés
AU - Fierro-Medina, Ricardo
AU - Le Pape, Patrice
AU - Eduardo García-Castañeda, Javier
AU - Marcela Parra Giraldo, Claudia
N1 - Publisher Copyright:
© 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
PY - 2020/6/30
Y1 - 2020/6/30
N2 - Palindromic peptide LfcinB (21–25)Pal: RWQWRWQWR was synthesized by Solid Phase Peptide Synthesis (SPPS-Fmoc/tBu), purified by Reverse Phase Solid Phase Extraction (RP-SPE) and characterized by Reverse Phase High Performance Liquid Chromatography (RP-HPLC) and Matrix-Assisted Laser Desorption/Ionization-Time Of Flight Mass Spectrometry (MALDI-TOF MS). The antifungal activity of LfcinB (21–25)Pal against both ATCC strains and clinical isolates of C. albicans, C. glabrata, C. krusei, C. auris and C. tropicalis was evaluated. The palindromic peptide exhibited fungistatic and fungicidal activity against all yeast evaluated. The antifungal activity was dependent on peptide concentration in all cases. Additionally, LfcinB (21–25)Pal (25–50 μg/mL) combined with fluconazole exhibited a synergistic antifungal effect against C. tropicalis 883 and C. krusei 6258 (resistant to fluconazole). This study showed that the palindromic peptide derived from Lactoferricin B (LfcinB) exhibited significant antifungal activity against Candida spp, suggesting that this peptide could have a therapeutic application solely or in combination with fluconazole.
AB - Palindromic peptide LfcinB (21–25)Pal: RWQWRWQWR was synthesized by Solid Phase Peptide Synthesis (SPPS-Fmoc/tBu), purified by Reverse Phase Solid Phase Extraction (RP-SPE) and characterized by Reverse Phase High Performance Liquid Chromatography (RP-HPLC) and Matrix-Assisted Laser Desorption/Ionization-Time Of Flight Mass Spectrometry (MALDI-TOF MS). The antifungal activity of LfcinB (21–25)Pal against both ATCC strains and clinical isolates of C. albicans, C. glabrata, C. krusei, C. auris and C. tropicalis was evaluated. The palindromic peptide exhibited fungistatic and fungicidal activity against all yeast evaluated. The antifungal activity was dependent on peptide concentration in all cases. Additionally, LfcinB (21–25)Pal (25–50 μg/mL) combined with fluconazole exhibited a synergistic antifungal effect against C. tropicalis 883 and C. krusei 6258 (resistant to fluconazole). This study showed that the palindromic peptide derived from Lactoferricin B (LfcinB) exhibited significant antifungal activity against Candida spp, suggesting that this peptide could have a therapeutic application solely or in combination with fluconazole.
KW - Antifungal agents
KW - Candida
KW - Multidrug-Resistant
KW - Peptides
KW - Synergism
UR - http://www.scopus.com/inward/record.url?scp=85087119114&partnerID=8YFLogxK
U2 - 10.1002/slct.202001329
DO - 10.1002/slct.202001329
M3 - Article
AN - SCOPUS:85087119114
SN - 2365-6549
VL - 5
SP - 7236
EP - 7242
JO - ChemistrySelect
JF - ChemistrySelect
IS - 24
ER -